Tower Research Capital LLC (Trc) Editas Medicine, Inc. Transaction History

Tower Research Capital LLC (Trc)

  • $3.39 Billion
  • Q3 2025

A detailed history of Tower Research Capital LLC (Trc) transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 3,718 shares of EDIT stock, worth $9,666. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,718
Previous 15,925 76.65%
Holding current value
$9,666
Previous $35,000 65.71%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
SELL
$2.2 - $3.52 $26,855 - $42,968
-12,207 Reduced 76.65%
3,718 $12,000
Q2 2025

Aug 14, 2025
BUY
$0.98 - $2.35 $882 - $2,117
901 Added 6.0%
15,925 $35,000
Q1 2025

May 15, 2025
SELL
$1.14 - $3.2 $5,058 - $14,198
-4,437 Reduced 22.8%
15,024 $17,000
Q4 2024

Feb 13, 2025
SELL
$1.2 - $3.76 $31,953 - $100,121
-26,628 Reduced 57.78%
19,461 $24,000
Q3 2024

Nov 14, 2024
BUY
$3.39 - $5.96 $85,431 - $150,197
25,201 Added 120.65%
46,089 $157,000
Q2 2024

Aug 13, 2024
BUY
$4.67 - $7.28 $93,759 - $146,160
20,077 Added 2475.59%
20,888 $97,000
Q1 2024

May 15, 2024
SELL
$7.03 - $11.07 $39,515 - $62,224
-5,621 Reduced 87.39%
811 $6,000
Q4 2023

Feb 13, 2024
SELL
$6.25 - $11.11 $90,481 - $160,839
-14,477 Reduced 69.24%
6,432 $65,000
Q3 2023

Nov 14, 2023
BUY
$6.92 - $9.31 $32,613 - $43,878
4,713 Added 29.1%
20,909 $163,000
Q2 2023

Aug 14, 2023
BUY
$6.36 - $11.47 $73,197 - $132,008
11,509 Added 245.55%
16,196 $133,000
Q1 2023

May 09, 2023
SELL
$7.03 - $11.53 $160,185 - $262,722
-22,786 Reduced 82.94%
4,687 $34,000
Q4 2022

Feb 10, 2023
BUY
$8.32 - $13.21 $24,261 - $38,520
2,916 Added 11.87%
27,473 $243,000
Q3 2022

Nov 10, 2022
SELL
$12.16 - $19.42 $249,328 - $398,187
-20,504 Reduced 45.5%
24,557 $300,000
Q2 2022

Aug 15, 2022
BUY
$9.99 - $21.35 $404,125 - $863,671
40,453 Added 877.89%
45,061 $533,000
Q1 2022

May 12, 2022
SELL
$14.08 - $27.63 $61,698 - $121,074
-4,382 Reduced 48.74%
4,608 $87,000
Q4 2021

Feb 14, 2022
BUY
$26.55 - $40.57 $73,968 - $113,028
2,786 Added 44.91%
8,990 $238,000
Q3 2021

Nov 15, 2021
BUY
$39.27 - $72.94 $127,745 - $237,273
3,253 Added 110.23%
6,204 $254,000
Q2 2021

Aug 16, 2021
SELL
$31.29 - $56.64 $1.52 Million - $2.75 Million
-48,487 Reduced 94.26%
2,951 $167,000
Q1 2021

May 17, 2021
BUY
$39.71 - $90.58 $1.97 Million - $4.49 Million
49,570 Added 2653.64%
51,438 $2.16 Million
Q4 2020

Feb 16, 2021
SELL
$27.07 - $84.35 $208,168 - $648,651
-7,690 Reduced 80.46%
1,868 $131,000
Q3 2020

Nov 16, 2020
SELL
$28.06 - $37.16 $43,801 - $58,006
-1,561 Reduced 14.04%
9,558 $269,000
Q2 2020

Aug 13, 2020
BUY
$18.5 - $34.34 $205,701 - $381,826
11,119 New
11,119 $329,000
Q4 2019

Feb 07, 2020
SELL
$19.49 - $32.63 $21,302 - $35,664
-1,093 Closed
0 $0
Q3 2019

Nov 05, 2019
BUY
$22.49 - $26.81 $24,581 - $29,303
1,093 New
1,093 $25,000
Q2 2019

Aug 13, 2019
SELL
$20.48 - $27.76 $5,816 - $7,883
-284 Closed
0 $0
Q1 2019

May 14, 2019
SELL
$19.43 - $26.41 $10,900 - $14,816
-561 Reduced 66.39%
284 $7,000
Q4 2018

Feb 14, 2019
SELL
$18.19 - $31.79 $110,704 - $193,473
-6,086 Reduced 87.81%
845 $19,000
Q3 2018

Nov 13, 2018
BUY
$27.65 - $38.39 $188,960 - $262,357
6,834 Added 7045.36%
6,931 $221,000
Q2 2018

Aug 15, 2018
SELL
$31.4 - $41.01 $157 - $205
-5 Reduced 4.9%
97 $3,000
Q1 2018

May 15, 2018
SELL
$29.84 - $44.08 $2,297 - $3,394
-77 Reduced 43.02%
102 $3,000
Q4 2017

Feb 09, 2018
SELL
$21.89 - $31.34 $33,798 - $48,388
-1,544 Reduced 89.61%
179 $6,000
Q3 2017

Nov 14, 2017
BUY
$15.81 - $24.01 $27,240 - $41,369
1,723
1,723 $41,000

Others Institutions Holding EDIT

# of Institutions
226
Shares Held
46.2M
Call Options Held
841K
Put Options Held
304K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $179M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email